Founders and Starters
Professor Rene Bernards
Scientific Founder and Advisor- Rene Bernards: professor at Dutch Cancer Institute, trained at MIT and Harvard Medical School. Over 250 publications, 40,000 citations, founder of three companies prior to Oncosence (Agendia, Prolifix, Qameleon). His research produce 14 clinical trials (incl 2 global phase 3 trials). Target Identification, Pre Clincialto Clincial, Precision Medicine
Dr Liqin Wang
Principal Investigator at Sun Yat-sen University Cancer Center. Trained at the Dutch Cancer Institute, his work focuses on translational research in senescence and senolytics. He has published as first or corresponding author in prestigious journals such as Nature and Cell, and was honored with the H.G.K. Westenbrink Prize for my contributions to the field.
Rolf Jan Rutten
CEO- Rolf Jan Rutten: International management, early clinical development and BD experience. Founder and CEO of Audion Therapeutics, founder thromboDX(sold to Illumina) and DyblyAG. Translational Strategy, Clinical Trials
Bas van der Baan
Advisor- Bas van der Baan: Chief Clinical and BD Officer Agendia, founder thromboDx and QameleonTherapeutics. Precision Medicine, Companion Diagnostic, Market Access